Peripheral Artery Disease Market By Treatment / Device Type (Endovascular Devices, Pharmacological Therapies, Surgical Devices and Bypass Grafts); By Anatomical Site (Femoropopliteal Disease, Aortoiliac Disease, Infrapopliteal / Below-the-Knee Disease); By Disease Stage (Intermittent Claudication, Chronic Limb-Threatening Ischemia); By End User (Hospitals, Specialty Vascular and Cardiovascular Centers, Ambulatory Surgical Centers and Outpatient Clinics); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Peripheral Artery Disease Market Moves Toward Limb Preservation – (Updated On: 27-Sep-2026)

The Global Peripheral Artery Disease (PAD) Market was valued at USD 6.30 billion in 2025 and is projected to reach USD 9.37 billion by 2032, expanding at a CAGR of 5.85% during 2026–2032, according to Strategic Market Research.

 

Peripheral Artery Disease (PAD) Market refers to the commercial ecosystem of drugs, medical devices, diagnostic technologies, and treatment procedures used to diagnose, manage, and treat peripheral artery disease.

 

PAD represents a significant global cardiovascular disease burden, affecting an estimated 113 million to more than 200 million people worldwide. The disease prevalence increases significantly with age and is strongly associated with major risk factors including diabetes, smoking, hypertension, obesity, high cholesterol, and cardiovascular disease history. In the United States, approximately 10 million to 20 million people are estimated to have PAD, while global estimates indicate hundreds of millions of affected individuals.

 

The treatment landscape is shifting toward minimally invasive vascular procedures due to shorter recovery times, lower hospitalization requirements, and improved clinical outcomes. Endovascular interventions such as angioplasty, stent placement, atherectomy, drug-coated balloon therapy, and catheter-based plaque modification are widely adopted for restoring arterial flow. The United States performs approximately 1.3 million to 1.5 million endovascular PAD procedures annually, while global procedures exceed 4.5 million cases each year. Open surgical bypass remains important for complex blockages, long lesions, and advanced disease, particularly in patients with CLTI requiring femoropopliteal or femoral-tibial bypass procedures. The femoropopliteal segment accounts for approximately 66% of demand, making it a major target for peripheral vascular technologies.

 

Overall, the PAD market is transitioning toward a procedure-intensive, minimally invasive, and limb-preservation-focused treatment landscape, creating sustained commercial opportunities across endovascular devices, vascular surgery products, and chronic pharmacological management.

 

PAD Revenue Leaders and Emerging Treatment Hotspots

Leading Subsegments

By Treatment / Device Type — Endovascular Devices

Endovascular Devices are the leading treatment/device segment, capturing a 54% share with USD 3.402 billion in 2025 revenue and expected to expand at a CAGR of 6.65% during 2026–2032. These minimally invasive catheter-based solutions are widely used in peripheral artery disease (PAD) management to reopen narrowed or blocked arteries, improve blood circulation, and reduce symptoms associated with limb ischemia. Key technologies include balloon angioplasty catheters, drug-coated balloons, stents, atherectomy systems, and intravascular lithotripsy devices, which address plaque buildup, vessel narrowing, and calcified lesions.

By Anatomical Site — Femoropopliteal Disease

Femoropopliteal Disease is the leading anatomical segment in the Peripheral Artery Disease (PAD) landscape, representing a 66% share and USD 4.158 billion in 2025 revenue, with a projected CAGR of 5.75% during 2026–2032. Femoropopliteal disease refers to narrowing or blockages in the superficial femoral and popliteal arteries, which are the most frequently affected locations associated with intermittent claudication in PAD patients. Reduced blood flow through this segment often results in calf pain, muscle cramping, fatigue, and limited walking capacity. Management includes risk-factor control, antiplatelet therapy, lipid and blood pressure management, supervised exercise programs, and minimally invasive interventions such as angioplasty, drug-coated balloons, and stenting, while surgical bypass is used for complex or extensive lesions requiring long-term vessel restoration.

By Disease Stage — Intermittent Claudication

Intermittent Claudication represents the leading disease-stage segment in Peripheral Artery Disease (PAD), accounting for a 61% share, equivalent to USD 3.843 billion in 2025 revenue, and is projected to expand at a CAGR of 5.15% during 2026–2032. Intermittent claudication is a key clinical manifestation of PAD, occurring when atherosclerotic plaque buildup restricts blood flow to the lower extremities. The condition causes predictable muscle pain, cramping, or fatigue during walking or exercise due to reduced oxygen supply. It also serves as an indicator of broader cardiovascular risk and requires management through lifestyle modification, exercise therapy, medication, and diagnostic evaluation.

By End User — Hospitals

Hospitals lead the end-user segment with a 68% share, generating USD 4.284 billion in 2025 revenue, and are projected to expand at a CAGR of 5.35% during 2026–2032. Hospitals serve as key treatment centers for Peripheral Artery Disease (PAD) by providing comprehensive vascular care, including advanced diagnostic evaluation, endovascular procedures, and surgical revascularization. They utilize imaging techniques such as duplex ultrasound and CT angiography to assess arterial blockages, while performing angioplasty, stenting, and bypass procedures to restore blood flow. Hospitals also play a crucial role in managing critical limb-threatening ischemia (CLTI) through limb salvage strategies and amputation prevention programs.

By Geography — North America

North America holds the dominant regional position in the Peripheral Artery Disease (PAD) market, accounting for a 43% share valued at USD 2.709 billion in 2025 revenue, and is expected to grow at a CAGR of 5.25% during 2026–2032. The regional burden of PAD continues to rise due to the expanding elderly population, increasing prevalence of diabetes, obesity, and cardiovascular disorders. Growing awareness, improved vascular screening, and wider adoption of diagnostic and treatment approaches are supporting PAD management across healthcare systems in the region.

 

Fastest-Growing Subsegments

By Treatment / Device Type — Endovascular Devices

Endovascular Devices represent the fastest-growing treatment/device segment, expanding at a CAGR of 6.65% during 2026–2032 from USD 3.402 billion in 2025, accounting for a 54% market share. In Peripheral Artery Disease (PAD) treatment, these minimally invasive technologies are increasingly adopted to restore blood flow, reduce symptoms such as intermittent claudication, improve mobility, and help prevent severe outcomes including limb-threatening ischemia. The segment includes guidewires, angioplasty balloons, stents, atherectomy systems, and intravascular lithotripsy devices that address complex arterial blockages, plaque buildup, and calcified lesions, supporting the wider adoption of catheter-based vascular interventions.

By Anatomical Site — Infrapopliteal / Below-the-Knee Disease

Infrapopliteal or below-the-knee (BTK) disease is estimated to be the fastest-growing anatomical segment in the Peripheral Artery Disease (PAD) market, expanding at a CAGR of 8.05% during 2026–2032 from a 15% share, representing USD 0.945 billion in 2025 revenue. This segment involves narrowing or occlusion of tibial and peroneal arteries, which play a major role in maintaining blood supply to the lower leg and foot. BTK disease is strongly associated with advanced PAD cases, particularly chronic limb-threatening ischemia (CLTI), diabetes-related vascular complications, non-healing wounds, and higher amputation risk. The growing need for limb-salvage procedures, minimally invasive revascularization, and advanced endovascular therapies is supporting segment expansion.

By Disease Stage — Chronic Limb-Threatening Ischemia (CLTI)

Chronic Limb-Threatening Ischemia (CLTI) is the fastest-growing disease-stage segment within the Peripheral Artery Disease (PAD) Market, accounting for a 39% share and USD 2.457 billion in 2025 revenue. It is projected to expand at a CAGR of 7.15% during 2026–2032. CLTI represents the advanced stage of PAD, where severe arterial blockages significantly reduce blood flow to the limbs, leading to persistent ischemic pain, non-healing ulcers, tissue damage, and increased risk of major amputation. Rising prevalence of diabetes, aging populations, and growing demand for limb-preservation procedures are accelerating CLTI management adoption.

By End User — Ambulatory Surgical Centers and Outpatient Clinics

Ambulatory Surgical Centers (ASCs) and outpatient clinics are emerging as the fastest-growing end-user segment in the Peripheral Artery Disease (PAD) market, accounting for 11% share with USD 0.693 billion revenue in 2025 and projected to expand at a CAGR of 8.25% during 2026–2032. These facilities are increasingly used for minimally invasive peripheral vascular interventions, including angioplasty, stenting, and atherectomy, as PAD treatment shifts toward same-day, cost-efficient care models. Growing preference for outpatient procedures, reduced hospital dependency, and improved access to vascular care are accelerating adoption across these settings.

By Geography — Asia-Pacific

Asia-Pacific is anticipated to witness the fastest growth in the Peripheral Artery Disease (PAD) Market, expanding at a CAGR of 8.25% during 2026–2032, supported by a 22% revenue share equivalent to USD 1.386 billion in 2025. The region is experiencing rising PAD burden due to aging populations, increasing diabetes prevalence, and growing cardiovascular risk factors. Improved vascular screening programs, expanding healthcare infrastructure, and wider adoption of minimally invasive peripheral interventions are strengthening PAD diagnosis and treatment access across Asia-Pacific countries.

 

Evidence and Device Breadth Drive PAD Competition

Leading Companies

Medtronic

Medtronic is one of the leading companies in the PAD treatment landscape because of its established Peripheral Vascular Health business and IN.PACT drug-coated balloon franchise, particularly for femoropopliteal disease. In the quarter ended July 31, 2026, Medtronic reported USD 338 million in Peripheral Vascular Health revenue, compared with USD 302 million in the corresponding 2025 quarter, representing approximately 11.9% reported growth. Its IN.PACT Admiral DCB has extensive evidence across SFA and popliteal disease, long lesions, chronic total occlusions, and in-stent restenosis. The IN.PACT Global study included 1,535 patients across 64 sites, while the full cohort demonstrated 69.4% freedom from clinically driven target-lesion revascularization at five years. This combination of commercial scale, long-term clinical evidence, and broad endovascular use supports Medtronic's strong position in PAD revascularization.

Boston Scientific

Boston Scientific is another leading participant, with a PAD portfolio centered on drug-eluting stents, drug-coated balloons, atherectomy and other peripheral intervention technologies. Its Eluvia Drug-Eluting Vascular Stent targets symptomatic superficial femoral and proximal popliteal artery disease. In the IMPERIAL randomized trial, one-year primary patency reached 92.1% with Eluvia versus 81.8% with Zilver PTX, with clinical follow-up extending to five years. The company's broader financial scale also supports continued vascular investment: Boston Scientific generated USD 20.074 billion in total 2025 net sales, of which its Cardiovascular segment contributed USD 13.250 billion, although this figure includes cardiovascular businesses beyond PAD. Its continued expansion into vessel preparation and calcified-lesion treatment further strengthens its position across complex peripheral interventions.

Specialist Players Expand the PAD Treatment Toolkit

• Abbott — Strengthens below-the-knee PAD treatment through the Esprit BTK everolimus-eluting resorbable scaffold; two-year LIFE-BTK data showed 48% fewer repeat procedures versus balloon angioplasty.

• BD — Participates across PAD treatment through the Lutonix drug-coated balloon, LifeStent vascular stent, and Rotarex atherectomy/thrombectomy system; Rotarex evidence covering 2,107 patients reported 95.8% technical success.

• Cook Medical — Serves femoropopliteal PAD through the Zilver PTX drug-eluting peripheral stent, including lesions up to 300 mm, with long-term clinical evidence extending to five years.

• Philips — Supports PAD intervention through image-guided therapy, IVUS, atherectomy, drug-coated balloons and the Tack Endovascular System, addressing post-angioplasty dissections in above- and below-the-knee disease.

• AngioDynamics — Focuses on plaque modification through the Auryon Atherectomy System, including above- and below-the-knee lesions; its AMBITION BTK program is evaluating Auryon plus balloon angioplasty in critical limb ischemia.

• Terumo Interventional Systems — Provides peripheral access, lesion-crossing, angioplasty and stenting technologies through its R2P portfolio and MISAGO peripheral stent; OSPREY data reported 88.6% freedom from target-lesion revascularization and 82.9% sustained patency at one year.

 

Analyst View: Durable Patency Sets the Pace for PAD Innovation

The Peripheral Artery Disease market is increasingly shifting from conventional disease management toward earlier vascular intervention, minimally invasive revascularization, and long-term limb preservation. Treatment opportunities are expanding as clinicians address more complex femoropopliteal and below-the-knee disease, particularly among aging and diabetic patient populations. The strongest commercial opportunities are emerging around drug-coated balloons, advanced peripheral stents, atherectomy and plaque-modification systems, and technologies designed for challenging calcified lesions and chronic limb-threatening ischemia. At the same time, the migration of suitable procedures toward outpatient vascular centers is reshaping where treatment is delivered. Companies that can combine durable vessel patency, effective treatment of complex lesions, lower repeat-intervention requirements, and solutions suited to both hospital and ambulatory settings are positioned to capture higher-value opportunities across the evolving PAD treatment pathway.

 

Peripheral Artery Disease Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 6.30 Billion
Revenue Forecast in 2032	USD 9.37 Billion
Overall Growth Rate	CAGR of 5.85% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026–2032)
Segmentation	By Treatment / Device Type, By Anatomical Site, By Disease Stage, By End User, By Geography
By Treatment / Device Type	Endovascular Devices, Pharmacological Therapies, Surgical Devices and Bypass Grafts
By Anatomical Site	Femoropopliteal Disease, Aortoiliac Disease, Infrapopliteal / Below-the-Knee Disease
By Disease Stage	Intermittent Claudication, Chronic Limb-Threatening Ischemia (CLTI)
By End User	Hospitals, Specialty Vascular and Cardiovascular Centers, Ambulatory Surgical Centers and Outpatient Clinics
By Geography	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, France, Netherlands, China, India, South Korea, Japan, Brazil, Mexico, UAE, Saudi Arabia, South Africa
Market Drivers	shorter recovery times, lower hospitalization requirements, and improved clinical outcomes
Customization Option	Available upon request